Description: Key Insights Given the large stake in the stock by institutions, Pfizer's stock price might be vulnerable to their...

Description: Biotech stocks remain prevalent on the IBD 50 list of winning growth names. While many biotech names are extended, Stoke Therapeutics and Mirum Pharmaceuticals are both in or forming bases. Biotech stocks have made tremendous progress off April lows.

Description: JNJ's oncology sales surge on strong drug launches and pipeline momentum, raising the stakes for its ambitious $50B 2030 goal.

Description: The Global Nasal Drug Delivery Market presents opportunities driven by increased patient preference for non-invasive methods, rising chronic respiratory conditions, and innovations in nose-to-brain drug delivery for CNS treatments. Key players like GlaxoSmithKline and Pfizer are optimizing formulations to overcome permeability challenges. Nasal Drug Delivery Market Nasal Drug Delivery Market Dublin, Nov. 28, 2025 (GLOBE NEWSWIRE) -- The "Nasal Drug Delivery Market - Global Industry Size, Share,

Description: While Pfizer has lagged behind the broader Dow Jones Industrial Average, Wall Street remains optimistic about the stock.

Description: Pfizer Inc. (NYSE:PFE) is one of the best low volatility large cap stocks to invest in. On November 24, Guggenheim lifted the price target on Pfizer Inc. (NYSE:PFE) to $35 from $33 while keeping a Buy rating on the stock. The firm told investors that Pfizer Inc.’s (NYSE:PFE) acquisition of Metsera, Inc. marks a “a […]

Description: PFE's oncology gains and obesity re-entry contrast with NVO's GLP-1 pressures in this in-depth comparison of two healthcare giants.

Description: NVO seeks an expedited FDA review for a higher 7.2 mg dose of Wegovy after strong weight-loss results in its STEP UP study.

Description: These top dividend stocks could intrigue a wide range of investors.

Description: Novo Nordisk jumps after phase II data show amycretin offers significant weight loss and HbA1c level reductions in type 2 diabetes patients.

Description: ABBV's surging immunology sales and smoother LOE path stand out as both drugmakers face a pivotal 2026.

Description: Valneva said that antibody levels remained well above baseline across all six Lyme disease serotypes and all age groups in the trial.

Description: The Centers for Medicare & Medicaid Services said Tuesday it expects to achieve net savings of 44%,

Description: The weight loss drug market may approach almost $100 billion by the end of the decade.

Description: Antibody levels remained well above baseline across all six serotypes and age groups sixth month after third yearly booster doseNo safety concerns observed in any age group by an independent Data Monitoring Committee (DMC)Results confirm benefits of a yearly vaccination prior to each Lyme season Saint-Herblain (France), November 26, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced positive final immunogenicity and safety data from Phase 2 study, VLA15-221, of Lyme disease va

Description: The U.S. government negotiated lower prices in the federal Medicare program for 15 high-selling medicines including Ozempic, widening an effort to rein in drug costs. The new prices, which will take effect in 2027, shave 38% to 85% off the list prices for drugs for diseases including asthma, cancer and diabetes. The reductions are estimated to save Medicare, the health-insurance program for the elderly, $12 billion.

Description: Zolgensma is only approved for infants with spinal muscular atrophy. Older people will be able to use a new version of the treatment, called Itvisma.

Description: The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during a mid-stage trial, lifting shares in the company.

Description: J&J's 16.7% rise reflects stronger sales guidance, rapid pipeline advances and improving MedTech momentum amid a recovering sector.

Description: The trial proved so successful that Bayer plans to reach out to regulators in preparation for submitting the drug candidate for approval.

Description: This big pharma stock should be even more appealing to investors amid market turbulence.

Description: Pfizer and Astellas Pharma have received FDA approval for PADCEV, an antibody-drug conjugate, in combination with Keytruda as a neoadjuvant and adjuvant therapy for muscle-invasive bladder cancer in patients ineligible for cisplatin-containing chemotherapy, following strong results from the Phase 3 EV-303 trial. This milestone extends Pfizer’s reach in oncology by offering a much-needed treatment option for patients with limited chemotherapy alternatives and underscores ongoing progress in...

Description: As pharma’s U.S. facility investments top $370 billion over the next five years, there are a few things to keep in mind, according to construction experts.

Description: Bayer issued a "surprisingly positive" report for its blood thinner over the weekend, prodding Bristol Myers Squibb stock higher on Monday.

Description: Among those chosen to help in his move to City Hall are former Goldman Sachs Group Inc. partner Margaret Anadu, developer Jed Walentas and Kathy Wylde, head of the Partnership for New York City. Wylde and Anadu will serve on the Committee on Economic Development & Workforce Development, and Walentas will join the Committee on Housing, according to a statement from Mamdani’s transition team on Monday.

Description: President Trump is expected to unveil plans to lower healthcare costs, which could significantly impact the pharmaceutical industry. Additionally, Pfizer's (PFE) entry into the weight-loss drug space, joining Novo Nordisk (NVO) and Eli Lilly (LLY), will also likely make waves. Yahoo Finance Senior Reporter Brooke DiPalma and Yahoo Finance Senior Business Reporter Ines Ferré join Opening Bid host Brian Sozzi to take a closer look at one frequently overlooked pharmaceutical name: Moderna (MRNA). To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: A long-shot Ozempic trial collapse sends Novo Nordisk to its lowest levels since 2021, reigniting market fears.

Description: Merck gains FDA nod for Keytruda and Keytruda Qlex with Padcev in MIBC, marking the first PD-1 inhibitor plus ADC regimens for this patient group.

Description: The Urinary Tract Infection (UTI) Treatment Market is projected to grow from US$ 9.13 Billion in 2024 to US$ 11.64 Billion by 2033, at a CAGR of 2.73%. This expansion is driven by rising UTI prevalence, awareness of early diagnosis, and advancements in therapy. Key growth factors include aging populations, rising catheter-associated infections, and a growing female demographic. Innovative treatments like vaccines and probiotics are gaining traction amid antibiotic resistance. North America leads

Description: LLY hits a historic $1T valuation as booming GLP-1 sales from Mounjaro and Zepbound drive growth and expand momentum across its portfolio.

Description: RVL Pharmaceuticals, Inc and its affiliates (together, "RVL") today announced a series of senior leadership appointments to strengthen the organization and position the company for accelerated growth across its business, including its flagship product, Upneeq® (oxymetazoline hydrochloride ophthalmic solution), 0.1%.

Description: NEW HAVEN, Conn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that multiple abstracts on vepdegestrant (ARV-471) have been accepted for presentation at the upcoming San Antonio Breast Cancer Symposium (SABCS), taking place December 9–12, 2025 in San Antonio, Texas. Vepdegestrant is a novel investigational PROTAC estrogen receptor (ER) degrader which is b

Description: UnitedHealth Group Incorporated (NYSE:UNH) is among the stocks Wall Street analysts are watching closely. On November 11, Wells Fargo analyst Stephen Baxter reaffirmed a Buy rating on UnitedHealth with a price target of $400. Earlier on November 3, a Barclays analyst had also maintained his Buy rating and a $386 price target. Analysts’ opinion on […]

Description: For those with decades left in their investing journey, these top healthcare stocks could be worthy portfolio contenders.

Description: Wondering if Pfizer is a smart buy at today's price? You are not alone, especially as value-focused investors begin to focus on the stock. Pfizer's performance has been mixed lately. Shares dipped just 0.1% in the last week, inched up 1.3% over the past month, but are still down 5.9% year to date despite a 4.7% return over the last twelve months. Recent headlines about Pfizer have focused on its latest product developments and major moves in the pharmaceutical sector, generating speculation...

Description: A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut.

Description: RAHWAY, N.J., November 21, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment, for the treatment of adult patients with muscle-invasive bladder cancer (MIBC) who a

Description: Health care stocks were higher late Friday afternoon, with the NYSE Health Care Index and the Health

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: NEW YORK & TOKYO, November 21, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV® (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate (ADC), in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), as neoadjuvant treatment and then continued after cystectomy

Description: Watch the Video I began the conversation with Lee by noting how rarely investors stop to consider how dramatically the upper ranks of the stock market have changed. When we looked back twenty five years, the list of dominant companies in the S&P 500 was almost unrecognizable compared with today. What the Top of the ... The Great S&P 500 Shakeup Leaves Microsoft and Oracle the Last Giants Standing

Description: Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Description: The drugmaker may not continue to lag the market for much longer.

Description: Pfizer's new and acquired drugs lift non-COVID revenue, with recent launches and Seagen products driving momentum into 2026 despite looming LOEs.

Description: Earlier this week, Phillip Frost, CEO and Chairman of OPKO Health, together with Frost Gamma Investments Trust, acquired OPKO Health shares totaling US$737,747, substantially increasing his direct and indirect holdings in the company. This insider activity coincided with Jefferies downgrading OPKO Health from Buy to Hold due to concerns regarding stagnant sales guidance for Ngenla, the firm's growth hormone treatment developed with Pfizer. Let's explore how Phillip Frost's significant...

Description: BMY ends its Librexia ACS study after an interim review shows milvexian is unlikely to meet goals, while other late-stage studies continue.

Description: Viking Therapeutics completes enrollment in its phase III VANQUISH-1 obesity study, surpassing targets and marking rapid progress for its VK2735 program.

Description: For Big Pharma, the triumph of developing a new lifesaving blockbuster drug that generates billions in revenue is inevitably followed by the reality that drug patents have an expiration date. It’s a challenge that Bristol Myers Squibb is navigating in real time as it faces a sharp drop in sales of Revlimid, a leading treatment for multiple myeloma that lost patent protection in 2022. Other flagship products approaching their loss of exclusivity in 2028 include Eliquis, a blood thinner, and the intravenous formulation of the cancer immunotherapy Opdivo.

Description: When the AI bubble bursts, Altria will look like a pretty good investment again. It has paid out billions in dividends over the years, and that is unlikely to stop.

Description: The company's earnings fell by 21% last quarter.

Description: Targeted chemotherapy is here. So-called antibody drug conjugates could flip the toxic paradigm on its ear, helping more patients.

Description: Bank of Montreal (BMO) announced five new Canadian depositary receipts (CDRs) will begin trading on the Cboe Canada exchange today. The initial offering of these new CDRs has closed.

Description: A day after the White House proclaimed that Saudi Arabia boosted its spring pledge to invest $600 billion in the US to a tidy $1 trillion during Crown Prince Mohammed bin Salman’s visit to Washington, DC, President Donald Trump said companies from both nations inked $270 billion in deals at a US-Saudi business forum. No timeline was given for Saudi Arabia’s $1 trillion in investments and, while the US-Saudi Investment Forum on Wednesday drew corporate royalty from Chevron, Tesla, Nvidia, Qualcomm, Cisco, General Dynamics, Pfizer and more, it wasn’t immediately clear which companies inked deals. Trump did say GE Aerospace will “deliver dozens of new engines” while a handful of other pacts, while short on financial details, highlighted some international bargaining.

Description: Health care stocks fell late Wednesday afternoon with the NYSE Health Care Index easing 0.1% and the

Description: Agios reported the results of the study on Wednesday, and they were mixed. Most patients didn’t experience much of a difference.

Description: Pfizer (PFE) CEO Albert Bourla sits down with Yahoo Finance Executive Editor Brian Sozzi to talk about when consumers can expect to see lower drug prices. Pfizer is among the companies that have made deals with the White House on pharmaceutical pricing. Make sure to watch Yahoo Finance's full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: Ewing sarcoma is a rare but increasing concern in pediatric oncology, defined by the EWSR1-FLI1 fusion gene. Primarily affecting individuals aged 10-20, it manifests in bones and soft tissue, often metastasizing early. The rising prevalence highlights urgent needs for advanced treatments, fueled by global healthcare investment and growing early-detection capacities. However, high treatment costs pose financial challenges. Key industry players like Salarius Pharmaceuticals and Pfizer are innovati

Description: The global bacterial vaginosis market is experiencing rapid growth, fueled by a rise in incidence due to lifestyle and hygiene changes. Increasing awareness is driving demand for innovative treatments, including probiotics and precision medicine. Investments from both the government and private sector, especially in women's health, are accelerating market growth. However, challenges such as side effects of current treatments persist. As research advances and emphasis on sustainable solutions int

Description: The global metrorrhagia market is expanding due to an increasing prevalence of gynecological disorders like uterine fibroids and hormonal imbalances, fueling the demand for effective treatments. Despite challenges such as high diagnostic costs and limited awareness, advancements in hormonal and non-hormonal therapies are driving patient adoption. Key developments include targeted drug formulations, innovative surgical techniques, and emerging therapies like selective progesterone receptor modula

Description: Nona Biosciences, a global biotechnology company providing integrated solutions for biological drug discovery and development from I to I® (Idea to IND), today announced a non-exclusive license agreement with Pfizer designed to accelerate preclinical antibody discovery across a range of potential disease indications.

Description: Saudi Crown Prince Mohammed bin Salman’s overtures to U.S. political and business leaders will continue Wednesday, but on somewhat friendlier terms. Bin Salman, the de facto ruler of Saudi Arabia, took questions from the press alongside President Donald Trump Tuesday. The event turned combative after Trump bristled at a reporter’s probing questions.

Description: Pfizer Inc. (PFE) finally topped Novo Nordisk (NVO) to buy Metsera after Novo raised its bid twice. Metsera’s crown jewel is MET-097i, a weekly and monthly injectable GLP-1 asset that’s about to begin Phase III development, writes John McCamant, editor of Medical Technology Stock Letter.

Description: Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal

Description: Signs of a weight loss price war appeared to worry investors early Monday, and Lilly and Novo stocks were down.

Description: The market is hopping with interesting news.

Description: Pfizer (PFE) shares have shown resilience, with a modest uptick over the past week and month. Investors are keeping an eye on the stock’s performance as the company navigates market trends and changing sentiment. See our latest analysis for Pfizer. Despite a challenging year for many large-cap healthcare names, Pfizer's recent momentum hints at a shift in sentiment. While the share price is still down for the year to date, the one-year total shareholder return has turned positive. This...

Description: J&J's $3.05B move for Halda adds targeted oral cancer therapies and expands its prostate cancer pipeline amid rising pharma M&A.

Description: PFE trades above its 50-day SMA on recent gains from the Metsera acquisition and a drug pricing agreement with the U.S. administration.

Description: The global renal anemia market is experiencing significant growth, driven by advancements in therapeutic options, increased diagnostic accuracy, and enhanced healthcare investments in the U.S., Europe, and emerging markets. The market is reshaped by the expansion of erythropoiesis-stimulating agents (ESAs), iron supplements, and novel oral hypoxia-inducible factor prolyl-hydroxylase inhibitors (HIF-PHIs). Rising awareness about untreated renal anemia complications, such as fatigue, fuels the dem

Description: The global hemophilia market is experiencing robust growth, fueled by advances in gene therapy and recombinant clotting factors. Increased awareness and healthcare investment worldwide are expanding access to innovative treatments such as extended half-life therapies and novel biologics, enhancing patient outcomes. The U.S. market drives this expansion, supported by a strong healthcare infrastructure and evolving regulatory landscape. However, high therapy costs and regulatory hurdles remain cha

Description: The global pleural effusion market is experiencing steady growth due to advancements in medical treatments and diagnostic tools, increased awareness of respiratory health, and a rising demand for effective management solutions. Key drivers include the development of advanced drainage systems, anti-inflammatory drugs, and minimally invasive treatments like thoracentesis and pleurodesis. As awareness of pleural effusion's risks increases, early detection and intervention remain crucial. Despite ch

Description: The Global Microscopic Polyangiitis (MPA) market is experiencing growth driven by the adoption of biologic therapies, which offer targeted mechanisms and improved relapse prevention. MPA, a rare ANCA-associated vasculitis, affects small blood vessels, posing risks to vital organs such as kidneys and lungs. Diagnosis requires ANCA testing and biopsies, with treatment involving corticosteroids, cyclophosphamide, and rituximab, alongside new therapies like avacopan. Despite challenges like high bio

Description: Hemophilia A, a rare genetic disorder marked by a deficiency of clotting factor VIII, leads to prolonged bleeding and joint damage. Enhanced treatment options, like extended half-life clotting factors and gene therapy, are revolutionizing patient outcomes through less frequent dosing and potential long-term solutions. Rising awareness and improved diagnostics hasten early detection, boosting demand. However, high treatment costs and regulatory hurdles present challenges. Key players like Alnylam

Description: The Hemophilia B market is growing rapidly due to advancements in gene therapy and diagnostics. This rare genetic disorder, caused by F9 gene mutations, primarily affects males. Revolutionary treatments like Hemgenix and Beqvez offer potential functional cures by reducing bleeding rates. Early detection using next-generation sequencing enhances patient management and personalized care. Despite challenges such as high costs and limited long-term safety data, leading companies like UniQure and Pfi

Description: Nuvalent will discuss the data for TKI pre-treated ALK-positive NSCLC patients with the FDA in a pre-NDA meeting

Description: Eli Lilly might soon join them for a far different reason: the weight-loss bonanza. This year, Lilly has moved sharply ahead, securing Medicare access while widening its lead over Wegovy maker Novo Nordisk That is why investors shouldn’t assume the rally stops at a trillion. Lilly only began selling its weight-loss drug Zepbound in late 2023, and the Food and Drug Administration only declared an end to a supply shortage of obesity drugs last year.

Description: [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global NUT Midline Carcinoma Treatment Market size & share revenue was valued at approximately USD 22.67 Billion in 2024 and is expected to reach USD 26.13 Billion in 2025 and is expected to reach around USD 93.34 Billion by 2034, at a CAGR of 15.26% between 2025 and 2034. The key market players listed in the report with their sales, revenues and strategies are Merck & Co.

Description: Johnson & Johnson said Monday it's putting up $3.05 billion to buy privately held cancer player Halda Therapeutics.

Description: Halda is testing a prostate cancer drug. J&J says that with the acquisition it will gain a platform for treating “diseases beyond oncology.”

Description: Consider buying Medtronic for its dividend and Pfizer for its turnaround potential if you are looking for attractive healthcare investments in November.

Description: Merck's $9.2 billion proposed Cidara acquisition will add CD388 to the pipeline, boosting the respiratory portfolio and fueling its ongoing strategic M&A momentum.

Description: By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT Third Quarter 2025 Financial and Operational Review Protalix BioTherapeutics, Inc. (NYSE:PLX) announced 3Q:25 financial and operational results in a November 13 th , 2025, press release and in its Form 10-Q filing. The reports were followed by a conference call, which discussed recent achievements, regulatory updates, trial

Description: Pfizer is a pharmaceutical industry giant facing normal pharmaceutical industry headwinds; it will survive.

Description: At Yahoo Finance Invest 2025, Albert Bourla and Ed Bastian shared the values that helped them lead companies through crisis.

Description: The company has been on an acquisition spree for years, and this one may be the most important yet.

Description: BioNTech (NasdaqGS:BNTX) shares caught investors’ attention after Pfizer revealed plans to sell its remaining stake in the company through an overnight block trade. This announcement prompted a wave of trading activity and market discussion. See our latest analysis for BioNTech. BioNTech’s share price has edged down nearly 2% this year, with momentum cooling further in recent months as investors weigh Pfizer’s exit and slowing Covid-19 vaccine revenues against a robust pivot back to oncology...

Description: Pfizer's fair value estimate has inched upward recently, rising from $28.86 to $29.08 per share. The discount rate has climbed slightly as well. Analysts note this shift reflects a blend of enthusiasm for new pipeline additions alongside prudent awareness of industry headwinds. Stay tuned to discover how evolving market developments continue to shape Pfizer's investment outlook and what to watch going forward. Analyst Price Targets don't always capture the full story. Head over to our Company...

Description: Gain insight on bidding wars in the pharmaceuticals sector, Novo Nordisk and more in the latest Market Talks covering the health care sector.

Description: Now in a tug of war with Lundbeck, Alkermes could either lose out on a marketed sleepiness drug or end up paying significantly more than it had hoped.

Description: Shares of global pharmaceutical company Pfizer (NYSE:PFE) fell 2.5% in the morning session after the company cut its stake in its pandemic partner BioNTech by more than half, a move that overshadowed other company developments.

Description: The executive, who brought Novo’s first weight-loss shot to market, had to spend part of the meeting explaining why proposed board member, Mikael Dolsten, 67, withdrew just a day ago because of an “issue with a former employer.” “We had very much looked forward to working together with Mikael Dolsten,” Sorensen said. Pfizer’s acquisition of Metsera closed on Thursday making Novo and its US rival clear competitors in the hottest and fastest-growing pharmaceutical market.

Description: Merck has agreed a $9.2bn takeover of Cidara Therapeutics, a drugmaker pioneering a long-acting antiviral that protects against flu, after overcoming...

Description: Pharma ETFs like IHE and PPH are rallying as strong Q3 earnings across major pharmaceutical companies lift sector sentiment.

Description: Move marks shift after years of mRNA collaboration that produced COVID-19 vaccine.

Description: Pfizer quickly consummated the $10 billion buyout after one-upping Novo Nordisk. Elsewhere, Lundbeck submitted a rival offer for Avadel Pharmaceuticals and Zealand Pharma dropped an obesity drug.

Description: Agentic AI is making its way into pharma marketing — and raising a slew of potential challenges around regulations and ethics.

Description: Merck is nearing a deal to buy Cidara Therapeutics, a drugmaker pioneering a long-acting antibody medicine that protects against flu, after besting...

Description: Bagsværd, Denmark, 13 November 2025 – Today, it was announced that Mikael Dolsten will not seek election to the Board of Directors at the upcoming extraordinary general meeting on 14 November 2025, as otherwise announced in the notice convening the Extraordinary General Meeting. Earlier today, Mikael Dolsten, who most recently served as the Head of R&D at Pfizer, informed Novo Nordisk that, in spite of his desire to join, he has decided to withdraw his candidacy to the Novo Nordisk Board of Dire

Description: Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index and the Health

Description: Pfizer CEO Albert Bourla says RFK Jr.'s appointment was not up to him, but he has found common ground with the vaccine skeptic.

Description: US drugmaker Pfizer said Thursday that it has completed its acquisition of biotech firm Metsera, closing a deal worth up to $10 billion after a fierce bidding war.It had offered to acquire Metsera for up to $86.25 per share, making the deal worth around $10 billion.

Description: Health and Human Services Secretary Robert F. Kennedy, Jr. has come under fire for his views on vaccines. In an interview with Yahoo Finance, Pfizer (PFE) CEO Albert Bourla says that Kennedy wouldn't have been his pick to lead HHS. Find out why in the video above. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: The sector is up almost 7% since the start of November, while the broader market is down more than 1%.

Description: Starboard’s Jeff Smith says activism isn’t about destruction — it’s about discipline, efficiency, and motivating complacent CEOs.

Description: Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.

Description: $508M share sale marks end of a Covid-era alliance--just as Pfizer doubles down on weight-loss moonshots

Description: Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to discuss the future of medicine and pharmaceuticals, and what impact he believes artificial intelligence (AI) will have. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: All three major US stock indexes were down after midday trading Thursday, following President Donald

Description: Pfizer CEO Albert Bourla told Yahoo Finance that Pfizer has a "right to win" on the obesity drugs that have become a major market.

Description: Fresh off Pfizer's (PFE) $10 billion battle to acquire Metsera (MTSR), Pfizer chairman and CEO Albert Bourla tells Yahoo Finance Executive Editor Brian Sozzi that the future for the pharmaceutical giant is bright. The company plans to enter the GLP-1 space by 2028 and aims to become a leader in the obesity market. Bourla also notes that the next big breakthrough in medicine could be aided by the use of artificial intelligence and discusses Pfizer's relationship with the White House. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: Pfizer (PFE) chairman and CEO, Albert Bourla, sits down with Yahoo Finance Executive Editor Brian Sozzi to share that Pfizer will enter the obesity market by 2028 after paying $10B to acquire Metsera (MTSR). The drugmaker won out over rival Novo Nordisk (NVO) in its bid for the company. Be sure to watch the full interview with Albert Bourla. For full interviews, highlights, and key insights, check out more from Yahoo Finance Invest.

Description: NEW YORK, November 13, 2025--Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.

Description: Nike upgraded, Dollar Tree downgraded: Wall Street's top analyst calls

Description: If you love investing or want to love investing, Yahoo Finance's annual Invest event is here to help!

Description: Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today reported financial results for the quarter ended September 30, 2025, and provided a financial and business update.

Description: The WifOR Institute’s ‘handprint’ quantifies positive socioeconomic impact of pharma products, positing a sustainability metric.

Description: Turn health into wealth with these three high-yielding dividend stocks.

Description: Dr. Richard Pazdur is “likely the best possible person for the role,” says one analyst. A calmer course for the FDA could add fuel to the recent run-up in biotech stocks.

Description: We recently published 12 Fresh Stocks Jim Cramer Discussed Along With His Latest Thoughts On Quantum Computing. Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently discussed. Amgen Inc. (NASDAQ:AMGN) is a drug company that makes and sells medicines for a wide variety of ailments, such as arthritis and ulcers. Just like he […]

Description: We recently published 12 Latest Stocks on Jim Cramer’s Radar . Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Jim Cramer has discussed pharma giant Pfizer Inc. (NYSE:PFE) several times recently. He has repeatedly commented on how the stock trades more like a bond rather than an equity due to its […]

Description: We recently published 12 Latest Stocks on Jim Cramer’s Radar . CoreWeave, Inc. (NASDAQ:CRWV) is one of the stocks Jim Cramer recently discussed. CoreWeave, Inc. (NASDAQ:CRWV) is a computing infrastructure firm that hosts GPUs and other hardware for AI software companies. Its inventory of NVIDIA GPUs has made the firm a key player in the […]

Description: Pfizer (PFE) managed to outbid competitor Novo Nordisk (NVO) to acquire Metsera (MTSR) in a deal valued at up to $10 billion. Pfizer stock is down by nearly 3% from this time a year ago. Robinhood (HOOD) Chief Investment Officer Stephanie Guild and Yahoo Finance senior reporters Brooke DiPalma and Ines Ferré discuss Pfizer's position in the healthcare space (XLV) and whether artificial intelligence could unlock new growth prospects for the pharmaceutical industry. Tune in on Thursday, November 13, for Yahoo Finance's interview with Pfizer CEO Albert Bourla at Yahoo Finance Invest. To watch more expert insights and analysis on the latest market action, check out more Opening Bid.

Description: The United States Dietary Supplements Market, projected to grow from US$ 54.24 billion in 2024 to US$ 103.56 billion by 2033, is driven by rising health awareness and demand for preventive healthcare, alongside growing fitness trends and an aging population. Busy lifestyles, online retail expansion, and innovation in supplement formulations further stimulate market growth. Popular for their role in enhancing immunity, fitness, and general health, dietary supplements include vitamins, minerals, a

Description: Value-driven plays abound in the top healthcare stocks.

Description: NEW YORK, November 12, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.

Description: The biotech start-up's stock had been rising rapidly in 2025.

Description: Pfizer Inc. (NYSE:PFE) is one of the best undervalued stocks to buy under $50. Pfizer Inc. (NYSE:PFE) received a rating update from TD Cowen analyst Steve Scala on November 4, who maintained a Hold rating on the stock and set a $30 price target. Pfizer Inc. (NYSE:PFE) reported its fiscal Q3 2025 results the same […]

Description: A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer offered insights on. Cramer discussed the company’s acquisition of Metsera during the episode. He commented: “There’s room for more than one winner in this race for GLP-1 weight loss supremacy, but some of these winners are going to be bigger than others. This morning, the […]

Description: Pfizer (PFE) has beat out Novo Nordisk (NVO) in the bidding war for obesity medicine company Metsera (MTSR). BMO Capital Markets managing director of biopharma equity research, Evan Seigerman, discusses why he thinks the acquisition worked out in the best way for all parties. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: Equity markets delivered a mixed response after Pfizer won the bidding war for anti-obesity drugmaker Metsera, as Metsera’s shares slipped but Novo Nordisk’s stock rose on news it was bowing out of the race.View on euronews

Description: The first thing that comes to mind when we speak about the S&P 500 is the biggest tech companies, high valuations, and fastest-moving giants. The S&P 500 is packed with the biggest and the best companies, celebrated for the price swings, cash flow, and high upside potential. The index is massive and is often associated ... 5 Highest Yielding Dividend Stocks in the S&P 500

Description: Pfizer is working to deal with typical business issues in the drug space, but its attempt at a solution has become very complicated.

Description: The Alpha-1 Antitrypsin Deficiency Disease market offers opportunities in developing targeted therapies due to an increasing diagnosed patient population, advances in genetic testing, and innovative treatments like enzyme replacement and gene therapies. Growing awareness and technological advancements further drive this niche market. Alpha-1 Antitrypsin Deficiency Disease Market Alpha-1 Antitrypsin Deficiency Disease Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Alpha-1 Antitrypsin Defic

Description: The Sickle Cell Disease Treatment Market offers significant opportunities with advancements in gene editing, stem cell therapies, and precision medicine driving innovation. Increased awareness and advocacy have spurred global initiatives for better diagnosis, research funding, and equitable access, addressing unmet needs and fostering partnerships. Sickle Cell Disease Treatment Market Sickle Cell Disease Treatment Market Dublin, Nov. 11, 2025 (GLOBE NEWSWIRE) -- The "Sickle Cell Disease Treatmen

Description: Pfizer Inc. ( NYSE:PFE ) just reported healthy earnings but the stock price didn't move much. Our analysis suggests...

Description: For most of Big Pharma, drug discounts have largely been about damage control. After months of tariff threats and talk of tougher pricing rules that weighed on their shares, several chief executives have made their way to the White House to announce drug-pricing deals in exchange for regulatory relief. For Eli Lilly’s   David Ricks and Novo Nordisk’s   Mike Doustdar, who paid their own visit to the White House last week, the calculus is different.

Description: The global vaccines market is projected to grow from USD 50.46 billion in 2025 to USD 63.66 billion by 2030, achieving a CAGR of 4.8%. Key drivers include high rates of infectious diseases, technological innovations, and robust government support. The pneumococcal and multivalent vaccine segments dominate due to rising pneumococcal infections and demand for comprehensive immunization, respectively. The Asia Pacific region is the fastest-growing market, driven by increased public health initiativ

Description: Three large pharmaceutical makers are jockeying for position in the rapidly expanding market for GLP-1 drugs.

Description: Pfizer not only beat expectations last quarter, but also boosted its guidance.

Description: Novo Nordisk Climbs After Dropping Out of Bidding War for Metsera

Description: Pfizer’s third quarter results reflected ongoing challenges in its COVID-19 franchise, but management pointed to solid growth in non-COVID products and disciplined cost management as key drivers of performance. CEO Albert Bourla emphasized the company’s ability to deliver adjusted earnings above expectations, noting, “Our business is performing well, and we are raising the range of our adjusted diluted EPS guidance for full year 2025.” The quarter saw operational declines in legacy COVID-19 prod

Description: Metsera stock toppled Monday after the buyout battle with Pfizer and Novo Nordisk ended. Pfizer will acquire Metsera for up to $10 billion.

Description: Gain insight on Pfizer’s purchase of Metsera, Roche’s fenebrutinib results, and more in the latest Market Talks covering the health care sector.

Description: ↗️ TSMC (TSM, TW:2330): The contract chip maker's sales rose last month at the slowest pace since February 2024, but remained in double-digits. Its American depositary receipts were up 3.1%, part of a broader rebound in technology stocks.

Description: Metsera falls sharply after Pfizer agrees to buy the weight-loss drug start-up in a deal that could be worth more than $10 billion.

Description: After losing out to Pfizer for a weight-loss drug startup, Novo Nordisk will now have to count more heavily on its own research labs for new drugs, even as it’s likely to continue to pursue other deals. Novo Nordisk’s near-term focus is to launch a pill form of Wegovy, the popular weight-loss drug it first launched in 2021 as a weekly injectable. Novo Nordisk has applied for Food and Drug Administration approval, and expects a decision by year end.

Description: Health care stocks rose late Monday afternoon with the NYSE Health Care Index adding 0.8% and the He

Description: Health care stocks rose Monday afternoon with the NYSE Health Care Index and the Health Care Select

Description: Late Friday, after a dramatic bidding war, he learned he’d finally claimed his prize. Bourla found out at around 9 p.m. that evening, according to people familiar with the matter, that the board of Metsera Inc., a three-year-old biotech startup developing a new generation of weight-loss drugs, had voted unanimously to accept Pfizer’s takeover offer of as much as $10 billion. It was the climax of a Wall Street duel that had pitted Pfizer against the Danish pharmaceutical giant Novo Nordisk A/S – and a deal that is poised to set the global drug industry’s pecking order for years to come.

Description: The win gives Pfizer a long-awaited foothold in the fast-growing obesity drug market.

Description: The Nasdaq Composite and S&P 500 were up in late-morning trading Monday, while the Dow Jones Industr

Description: Novo Nordisk Shares Pop After Stepping Back From Metsera Chase

Description: Alto Neuroscience, Autolus Therapeutics, Ascendis Pharma and Immuneering are gearing up to report Q3 results that could top expectations.

Description: Metsera Plunges After Pfizer Secures Revised $86-Per-Share Merger Deal

Description: Pfizer wins Metsera after antitrust warning derails Novo's $9B bid; investors reward financial discipline over deal chasing.

Description: On September 22, Pfizer announced a deal to acquire the shares of promising weight-loss drug start-up Metsera for $5.5bn. On Friday night Metsera...

Description: The Danish drugmaker's shareholders appear relieved that it hasn't overpaid for largely unproven treatments.

Description: <body><p>STORY: Shares in Novo Nordisk rose on Monday (November 10).</p><p>Investors bought in after the Wegovy maker lost out to Pfizer in a $10 billion bidding war for U.S. biotech Metsera.</p><p>Market watchers saw its offer as too complex.</p><p>The Danish drugmaker has also come under more pressure over governance.</p><p>That after Norway's sovereign wealth fund said it would abstain when Novo shareholders vote this week on a new board.</p><p>Pfizer said late Friday it had secured a deal for obesity drug developer Metsera.</p><p>It was a setback for Novo as it tries to compete with rival Eli Lilly in the weight-loss drug market.</p><p>Novo had started the bidding war in late October with an unsolicited offer a month after Metsera and Pfizer agreed a deal.</p><p>The U.S. Federal Trade Commission told Novo and Metsera last week their proposed deal risked breaking U.S. antitrust laws.</p><p>Metsera cited the antitrust concerns in rejecting Novo's bid.</p><p>The Danish drugmaker confirmed Saturday it would withdraw from the race.</p><p>Novo's shares were up 2.6% by Monday afternoon.</p><p>The stock has lost more than 70% of its value since June last year.</p></body>

Description: Pfizer secures a $10B deal to buy Metsera, ending its fierce bidding war with Novo Nordisk and reigniting its push into the obesity market.

Description: Morning Brief host Julie Hyman tracks several of the day's top trending stock tickers, including Pfizer (PFE) outbidding Novo Nordisk (NVO) in its acquisition of Metsera (MTSR), monday.com (MNDY) shares diving nearly 20% in Monday's premarket after falling short of revenue forecast estimates, and Instacart (CART) — which operates as Maplebear, Inc. — beating its third quarter earnings estimates. To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: US equity futures were up ahead of Monday's opening bell as traders monitored a potential breakthrou

Description: Is your portfolio truly prepared for year-end and 2026?

Description: Skepticism around sky-high tech valuations and a continued dearth of economic data set up the week for investors.

Description: Haleon plc (NYSE:HLN) is one of the stocks Jim Cramer recently discussed. Cramer highlighted the stock’s struggles, as he commented: “With Kimberly-Clark shelling out nearly $49 billion to buy Kenvue, which was originally J&J’s over-the-counter medicine business, I think it’s time to check in with Haleon, the former consumer business of GlaxoSmithKline and Pfizer… Oh, […]

Description: U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a bidding war against Novo Nordisk, the Danish drugmaker behind weight-loss treatments Ozempic and Wegovy. Metsera, based in New York, has no products on the market, but it is developing oral and injectable treatments. The deal comes as Pfizer is attempting to develop its own stake in that market, several months after ending development of a potential pill treatment for obesity.

Description: There's no need to break the bank to get your hands on excellent dividend payers.

Description: The founders of Metsera had a battle to buy their company. It’s their second time striking deal gold.

Description: <body><p>STORY: U.S. drugmaker Pfizer has clinched a $10 billion deal for obesity drug developer Metsera.</p><p>It ended the biotech bidding war with Danish rival Novo Nordisk, which announced Saturday (November 8) it would exit the race. </p><p>Metsera accepted a sweetened offer from Pfizer late Friday (November 7). </p><p>It cited U.S. antitrust risks in Novo's bid that it had previously called superior. </p><p>Novo said in a statement that it believed its offer structure was "compliant with antitrust laws."</p><p>Metsera’s drugs are projected to reach $5 billion in peak sales.</p><p>And this win hands Pfizer a way into the lucrative obesity drug market - even if Metsera’s treatments remain years away from hitting shelves. </p><p>It marks a blow for Novo as it tries to claw back lost ground against U.S. rival Eli Lilly.</p><p>The Danish drugmaker later said it’s advancing its own pipeline of treatment options for obesity…</p><p>And that it would "continue to assess opportunities for business development and acquisitions”.</p><p>Pfizer said it expects to close the merger soon after Metsera's November 13 shareholder meeting.</p></body>

Description: Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday. In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.

Description: The new proposal for the coveted obesity drug developer is more than double the size of Pfizer’s original bid and ends a squabble with Novo Nordisk that had resulted in lawsuits.

Description: We recently published 10 Stocks on Fire Amid Market Chaos. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera soared to a new all-time high on Thursday as buying appetite was bolstered by an intensifying billion-dollar bidding war from two pharmaceutical giants. At intra-day trading, Metsera, Inc. (NASDAQ:MTSR) climbed to a new […]

Description: Pfizer has clinched a deal worth up to $10bn to buy weight-loss start-up Metsera, capping a dramatic takeover battle after Ozempic maker Novo...

Description: Pfizer has agreed to buy the weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting Novo Nordisk following a heated bidding war. Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a share, Metsera said Friday. In September, Pfizer had agreed to buy Metsera for up to $7.3 billion.

Description: Metsera, Inc. (NASDAQ: MTSR) today announced that it has entered into an amended merger agreement with Pfizer, pursuant to which Pfizer will acquire Metsera for up to $86.25 per share, consisting of $65.60 per share in cash and a contingent value right (CVR) entitling holders to additional payments of up to $20.65 per share in cash.

Description: China’s commitment to innovation poses a long-term threat to U.S. companies. What it needs now is for its citizens to spend more.

Description: Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant government agencies for review and possible enforcement action for failure to participate in the National Advertising Division (NAD) inquiry.New York, NY, Nov. 07, 2025 (GLOBE NEWSWIRE) -- Following a challenge submitted by Pfizer, Inc., BBB National Programs’ National Advertising Division will refer BridgeBio Pharma Inc. to the relevant governmen

Description: Pfizer faces a fierce bidding war with Novo Nordisk over Metsera while securing a landmark U.S. drug pricing deal.

Description: Makers of weight-loss drugs saw their stocks surge in 2024, but no more. Now Trump's price deal adds new questions. Is the party over?

Description: We recently published 10 Stocks Jim Cramer Discussed Including His Palantir Deep Dive. Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently discussed. Pfizer Inc. (NYSE:PFE) reported its third-quarter earnings report yesterday. The results were a solid bunch of numbers that saw the firm post $16.65 billion in revenue and $0.87 in adjusted […]

Description: Lilly's Mounjaro and Zepbound continue to power growth as new launches boost momentum amid rising obesity competition.

Description: Ever wondered if Pfizer is a hidden gem or just treading water in today’s market? Let’s jump in and get to the bottom of whether the stock is truly worth your attention right now. Pfizer’s share price ticked up 2.3% this week, but has still slipped 5.4% in the last month and is down 6.6% year to date, with a modest 1.4% slide over the last year. Market watchers have been parsing several big headlines recently, including the company’s status as a leader in transformational therapies and some...

Description: Elon Musk's targets in order to hit his $1 trillion pay package are aggressive according to Tesla's (TSLA) board. Chris Rossbach from J.Stern agrees. This week concerns over an AI bubble have grown and shares of Nvidia (NVDA), Palantir (PLTR) and AMD (AMD) have faltered. The battle to buy Metsera (MTSR) is intensifying as both Novo Nordisk (NVO, NOVO-B.CO) and Pfizer (PFE) make bids for the obesity drug developer this week.

Description: Pharma rivals fight for control of next-generation obesity drug maker

Description: Factors like healthcare access, urbanization, and innovation, particularly in the U.S., France, and China, propel market expansion. Key players such as Pfizer, Bayer, and GlaxoSmithKline are fostering advancements in PMS therapies. Premenstrual Syndrome Treatment Market Premenstrual Syndrome Treatment Market Dublin, Nov. 07, 2025 (GLOBE NEWSWIRE) -- The "Premenstrual Syndrome Treatment Market Report by Drug Type, Type, Distribution Channel, Countries and Company Analysis 2025-2033" has been adde

Description: The founders of Metsera have a battle to buy their company. It would be their second time striking deal gold.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks highlighted as Jim Cramer responded to questions from Harvard Business School students. A student asked if the stock, given the company’s reputation for innovation, its decline of over 50% from its peak, and recent deals involving Metsera and the Trump administration on drug pricing, is now a […]

Description: US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Metsera stock surged Thursday on reports Pfizer has matched Novo Nordisk's $10 billion bid to buy the obesity-focused biotech.

Description: Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe

Description: Novo Nordisk’s chief executive challenged Pfizer to increase its bid for obesity start-up Metsera, as the Denmark-based drugmaker again bested...

Description: ↗️ Marvell (MRVL): Japan's SoftBank (JP:9984) explored a potential takeover of the U.S. semiconductor maker, intending to merge it with Arm (ARM), Bloomberg reported. Marvell shares closed up about 0.

Description: Contingent value rights have become common in biotechnology deals. More than half of all transactions this year include them, according to a Jefferies report in October.

Description: The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.

Description: Pfizer Inc. (NYSE:PFE) is one of the latest stocks on Jim Cramer’s radar. Cramer noted that the company could not perform as its entire industry is going through a tough time. He remarked: “…We also have a huge number of stocks that are sinking under their own weight, high-quality companies, real companies that are historically […]

Description: Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]

Description: Value stocks typically trade at discounts to the broader market, offering patient investors the opportunity to buy businesses when they’re out of favor. The key risk, however, is that these stocks are usually cheap for a reason – five cents for a piece of fruit may seem like a great deal until you find out it’s rotten.

Description: You cannot know the power of an investment unless you see the returns. Many think of dividend stocks as a way of generating cash income from their portfolio, but if you handle the income well, you can generate a higher total return through dividend reinvestment while boosting the long-term capital appreciation potential. Pfizer (NYSE: PFE), ... No Brainer Dividend Stocks To Buy Now

Description: On November 5, 2025, Novo Nordisk reported lower full-year sales and profit guidance following third-quarter results amid slowing growth in its obesity and diabetes businesses, while presenting new clinical data showing Wegovy’s benefits in lowering obesity-related health risks and pursuing regulatory approval for a higher dose. This period also saw heated legal battles with Pfizer over the acquisition of obesity biotech Metsera and the announcement of significant restructuring efforts,...

Description: MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

Description: AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.

Description: The company has paused some UK investment plans, citing declining government support for pharmaceutical innovation.

Description: Moderna’s third-quarter results weren’t as bad as they could have been, which was enough to trigger a rally in the stock on Thursday. Sales of Moderna’s respiratory syncytial virus, or RSV, vaccine remain negligible, and the company had a net loss of $200 million for the quarter. The quarter’s revenue of $1 billion beat the FactSet consensus estimate of $900 million.

Description: Here are some of the stocks that are on the move on Thursday, Nov. 6. Penn Entertainment (PENN) and Disney's (DIS) ESPN are ending their sports-betting agreement early. ESPN announced DraftKings (DKNG) as a new partner. There are new developments in the Pfizer (PFE) and Novo Nordisk (NVO) bidding war for Metsera (MTSR). A federal judge has agreed to dismiss a criminal case tied to two Boeing (BA) 737 MAX crashes. To watch more expert insights and analysis on the latest market action, check out more Market Catalysts.

Description: The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The "Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035" has been added to ResearchAndMarkets.com's offering. Co

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to a ruling in the litigation filed against the Company by Pfizer:

Description: Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk.

Description: NEW YORK, November 05, 2025--Pfizer Inc. (NYSE: PFE) today issued the following statement in response to the Delaware Chancery Court’s decision denying Pfizer’s request for a temporary restraining order to prevent Metsera, Inc. from terminating the existing merger agreement in favor of a competing proposal from Novo Nordisk.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Novo Nordisk stock reversed higher Wednesday, though the Wegovy and Ozempic maker cut its sales outlook for the third time this year.

Description: Moderna reports earnings early Thursday as investors wonder whether the biotech will run through its pandemic-era windfall before it stops losing money. The vaccine company had accumulated nearly $20 billion in cash by early 2022, thanks to the record-smashing sales of its Covid-19 shot, but has been losing billions of dollars a year since 2023. Management has said Moderna will have $6 billion left at the end of this year, will stop losing money in 2028, and won’t need to raise any new cash to bridge the gap.

Description: Without taking a firm position, the antitrust agency said Novo’s two-step deal structure may illegally sidestep requirements for a premerger review.

Description: Arvinas Inc (ARVN) showcases promising clinical progress and strategic partnerships, despite facing revenue declines and operational downsizing.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more heated.

Description: Intensifying competition, pricing pressure and copycat versions of its weight-loss drugs are holding back sales at the pharma giant.

Description: The CNS Summit Digital Innovation Index, created in partnership with IDEA Pharma, a division of SAI Med Partners, was unveiled during the CNS Summit annual meeting on November 4. The Index continues to assess and rank biopharma companies' progress in digital innovation across three key dimensions:

Description: – Presented positive data from Phase 1 clinical trials with ARV-102 in healthy volunteers and patients with Parkinson’s disease – – Presented preclinical data from ARV-806 demonstrating robust and differentiated activity in models of KRAS G12D-mutated cancer – – Presented preclinical data from ARV-027 demonstrating robust degradation of polyQ-AR in muscle, supporting further evaluation as a potentially disease-modifying therapy in SBMA – – Announced agreement with Pfizer to jointly select a thir

Description: Both companies have upped their bids, but Novo Nordisk comes armed with an extra $1.9bn.

Description: AMD beats expectations, Mamdani wins NYC mayoral election, Bitcoin briefly dips below $100,000, and more news to start your day.

Description: Competition and pricing weigh on the maker of Ozempic and Wegovy

Description: We recently published 10 Firms Stealing Market Spotlight Amid Bloodbath. Metsera, Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Tuesday. Metsera rallied to a new all-time high on Tuesday after pharmaceutical giant Novo Nordisk heated up efforts to snatch the company from Pfizer Inc. for an upsized $10 billion acquisition offer. In intra-day trading, […]

Description: Metsera on Tuesday called Novo Nordisk’s new $10 billion offer “superior” to rival Pfizer's bid of $8 billion.

Description: Three factors took Viking's shares higher in the month.

Description: The nucleic acid therapeutics market is growing due to rising genetic and chronic disease prevalence, expanding genomics R&D, and increased RNA therapeutics adoption. Key opportunities include precision medicine demand, mRNA applications, advanced delivery platforms, AI integration, and regulatory support. Nucleic Acid Therapeutics Market Nucleic Acid Therapeutics Market Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Nucleic Acid Therapeutics Market Report 2025" has been added to ResearchAndMark

Description: Global pharmaceutical company Pfizer (NYSE:PFE) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 5.9% year on year to $16.65 billion. On the other hand, the company’s full-year revenue guidance of $62.5 billion at the midpoint came in 0.5% below analysts’ estimates. Its non-GAAP profit of $0.87 per share was 37% above analysts’ consensus estimates.

Description: A new regulatory filing shows that billionaire investor Michael Burry's hedge fund Scion Asset Management purchased five million put options on Palantir Technologies, Inc. (NASDAQ:PLTR) and one million put options on NVIDIA Corp. (NASDAQ:NVDA), among ...

Description: Pfizer (PFE) posted notable earnings growth, with net profit margins improving to 15.6%, a lift from the previous period’s 7%. Year-over-year, EPS growth soared 133.3%, marking a sharp reversal from the company’s five-year average decline of 13.2% per year, even as a significant one-off loss of $4.7 billion weighed on the latest results. Looking ahead, investors are weighing the company’s stronger margins and attractive valuation multiples against forecasts for a 3.2% annual decline in...

Description: Jared Holz, Mizuho Securities Healthcare Equity Strategist, says he wouldn't be surprised to see one more bid from Pfizer. He tells Katie Greifeld and Matt Miller on "The Close" that Pfizer made it clear without saying so directly that its latest attempt may not be the final one.

Description: ↘️ Palantir (PLTR): Shares closed down 8%. The data-analytics company reported another quarter of record revenue but having more than doubled so far in 2025, the stock was priced for perfection. ↘️ Sarepta Therapeutics (SRPT): Shares tumbled 34% after the biotech company said results from a yearslong trial of two therapies for a rare muscle-wasting illness fell short of statistical significance.

Description: The revised bids are the latest unusual twist in the fight between big drugmakers over drug developer Metsera.

Description: Shares in data analytics software developer Palantir tumble even as the company tops analysts' earnings estimates.

Description: The Danish drugmaker has gone from steady to chaotic. Its fight with Pfizer to acquire Metsera is getting more and more heated.

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Pfizer stock dipped early Tuesday despite hiking its 2025 profit guidance, as third-quarter sales and earnings both toppled year over year.

Description: Despite a drop in COVID product demand, Pfizer Inc (PFE) surpasses EPS expectations and advances key strategic initiatives.

Description: Novo Nordisk said it would pay up to $10 billion to acquire obesity-focused Metsera, topping Pfizer's recently hiked $8.1 billion proposal.

Description: Health care stocks advanced late Tuesday afternoon with the NYSE Health Care Index and the Health Ca

Description: On November 4, 2025, Pfizer reported third-quarter earnings showing a year-over-year decline in revenue to US$16.65 billion and net income to US$3.54 billion, while reaffirming full-year revenue guidance between US$61.0 billion and US$64.0 billion. The company's results reflect ongoing operational pressures, challenges related to COVID-19 product demand, and the impact of legal disputes over its bid for obesity drug developer Metsera. We'll explore how Pfizer's ongoing legal battle over the...

Description: The Danish company’s latest offer is more than 30% about what Pfizer initially agreed to pay, not counting potential milestone payments.

Description: Pfizer reported lower third-quarter profit as demand for its Covid-19 vaccine and antiviral drug continued to decline.

Description: Pfizer shares were lower on Tuesday despite third-quarter financial results that came in ahead of expectations. Adjusted diluted earnings came in at $0.87 per share, well ahead of the $0.63 per share consensus estimate. The stronger-than-expected revenue came from older products, while cost cuts and lower-than-expected tax liabilities helped the bottom line.

Description: European stock markets closed mixed in Tuesday trading as the Stoxx Europe was down 0.30%, Germany's

Description: All three major US stock indexes were down in late-morning trading Tuesday, as concerns mount over v

Description: “Sometimes, we see bubbles,” Burry said in a recent X post. “Sometimes, there is something to do about it. Sometimes, the only winning move is not to play.”

Description: Albert Bourla: The past few months have been pivotal for Pfizer Inc. We are really excited about our future and confident that we are in a strong position to continue delivering value for patients and our shareholders. What I can say, is that our belief in the promise of the Pfizer Inc. and MedCera combination is strong, and unwavering, We are confident it will create substantial value for shareholders and advance innovation to bring important medicines to patients in the high-growth therapeutic area of obesity.

Description: Yahoo Finance Senior Reporter Allie Canal outlines what investors are watching on Tuesday, Nov. 4. Pfizer (PFE), Uber (UBER), Spotify (SPOT), and BP (BP) are among the companies releasing earnings ahead of the opening bell. AMD (AMD), Pinterest (PINS), Rivian (RIVN), and Cava (CAVA) will continue the wave of earnings after the closing bell. ADP (ADP) is set to release a new weekly labor market report amid the ongoing government shutdown. Watch the video above to learn more about the stories that the market is watching. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.

Description: The Nasdaq Composite and the S&P 500 advanced in an overall mixed session on Monday, with Amazon.com

Description: Third quarter earnings season is in full swing, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: Metsera called Pfizer's claims "nonsense" in a follow-up Monday to Pfizer's lawsuit against Metsera and Novo Nordisk.

Description: The 11th-hour attempt by Novo to snatch away Metsera, which Pfizer had agreed to buy in September, has upended debate around the company.

Description: US benchmark equity indexes were mostly higher after midday Monday amid a jump in Amazon.com (AMZN)

Description: Health care stocks declined Monday afternoon, with the NYSE Health Care Index shedding 0.3% and the

Description: These two leading drugmakers are fighting over a promising GLP-1 candidate.

Description: Pfizer has filed a second lawsuit against Novo Nordisk and obesity drug start-up Metsera, redoubling its fight to stop Novo’s bid for the biotech...

Description: The lawsuit says the merger would solidify Novo Nordisk’s market position as a leader in the field of obesity drugs by killing off a smaller competitor.

Description: Pfizer has now filed a suit in federal court, following its claim in state court on Friday. It is riding Trump-era political currents in its efforts to save the deal.

Description: The GLP-1 drug market has surged dramatically in the past four years, driven by soaring demand for weight-loss treatments that also tackle related conditions like diabetes and heart disease. Valued at over $100 billion today, the sector is projected to exceed $150 billion by 2030 as more patients seek effective therapies. Viking Therapeutics (NASDAQ:VKTX) is ... Viking Therapeutics Could Be Pharma’s Next Big Buyout Target

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer had in this week’s game plan. Cramer discussed the future possibilities of the stock, as he commented: “Now, will Pfizer break out from the $25 level? Oh, it’s been a dull run for this former growth drug stock as shareholders seem to be satisfied with […]

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:

Description: (Updates to add comment from Novo Nordisk in the sixth paragraph.) Pfizer (PFE) said late Friday

Description: There are a number of stocks on the move on Monday, Nov. 3. Kimberly-Clark (KMB) announced it is buying Kenvue (KVUE) in a deal valued at $48.7 billion. Iren (IREN) shares are soaring after striking a $9.7 billion deal with Microsoft (MSFT). Pfizer (PFE) is suing to block Novo Nordisk's (NVO) bid for obesity startup Metsera (MTSR). To watch more expert insights and analysis on the latest market action, check out more Morning Brief.

Description: NEW YORK, November 03, 2025--Pfizer Inc. today announced that it has filed a second lawsuit against Metsera, Inc., its controlling stockholders, and Novo Nordisk A/S in the United States District Court for the District of Delaware.

Description: Pfizer called Novo Nordisk’s last-minute bid to acquire Metsera “reckless and unprecedented”.

Description: These healthcare stocks are making strides in very important ways.

Description: The benchmark US stock measures were tracking in the green before the opening bell Monday as traders

Description: Global pharmaceutical company Pfizer (NYSE:PFE) will be announcing earnings results this Tuesday before market open. Here’s what you need to know.

Description: Vertex, Corteva, and many more will also report earnings. On the economic front, The Supreme Court will hear arguments on the legality of Trump’s tariffs, and ADP will release October employment data.

Description: Markets look set to enter the fifth full week of a US government shutdown as investors parse Powell's comments, news of a trade deal between Washington and Beijing, and another mammoth week of earnings.

Description: Novo Nordisk and Pfizer are showing some desperation in their gloves-off tussle for the obesity-drug assets of Metsera.

Description: Pfizer stock has dropped 50% over the past three years.

Description: The lawsuit escalates an unusual, high-profile battle between two large pharmaceutical companies over ownership of a coveted developer of obesity drugs.

Description: It is hard to get excited after looking at Pfizer's (NYSE:PFE) recent performance, when its stock has declined 9.4...

Description: The lawsuit says Novo Nordisk’s offer for drug startup Metsera isn’t reasonably likely to be completed.

Description: Metsera, Inc. (NASDAQ: MTSR) ("Metsera" or the "Company") today issued the following statement in response to litigation filed against the Company by Pfizer:

Description: Pfizer is suing over some unsolicited competition in its nearly $5 billion bid to buy the drugmaker Metsera. New York-based Pfizer said Friday after markets closed that it was suing Metsera and a third drugmaker, Denmark’s Novo Nordisk, over a bid for Metsera that Novo announced Thursday.

Description: Pfizer sued Metsera and Novo Nordisk on Friday to prevent Novo's proposed $6.5 billion takeover of the smaller obesity-focused company.

Description: Third quarter earnings season is ramping up, and analysts expect S&P 500 companies grew their profits by 8% during the quarter.

Description: NEW YORK, October 31, 2025--Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. in the Delaware Court of Chancery. The lawsuit asserts claims for breach of contract, breach of fiduciary duty, and tortious interference in contract arising from Metsera’s breach of its obligations under the merger agreement between Pfizer and Metsera.

Description: NEW YORK, October 31, 2025--Pfizer Inc. (NYSE: PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the "HSR Act"), with respect to Pfizer’s pending acquisition of Metsera (NASDAQ: MTSR).

Description: Pfizer (PFE) could leverage its White House connections to counter Novo Nordisk's (NVO) bid for obes

Description: Find insight on Eli Lilly, Novo Nordisk, Pfizer and more in the latest Market Talks covering Health Care.

Description: Pfizer's Q3 results are due on Nov. 4, with analysts eyeing $16.6B in sales and EPS of 66 cents as investors weigh the stock's next move.

Description: AbbVie stock dropped Friday after the biopharmaceutical company reported mixed results across its drug portfolios in the third quarter. Shares declined 4.7% to $217.50, putting AbbVie on pace for its lowest same-day percentage decrease since May 14, according to Dow Jones Market Data. Pharma peers traded mixed: Johnson & Johnson fell slightly while Pfizer gained 0.7%.

Description: <body><p>STORY: :: Novo Nordisk </p><p>Novo Nordisk has almost completed notifying employees impacted by the drugmaker's 9,000 job cuts.</p><p>That’s according to a LinkedIn post by CEO Mike Doustdar Friday. </p><p>As jobs were slashed globally, he added that the pace of informing people varied according to local laws. </p><p>It’s part of Doustdar’s restructuring drive which he launched last month. </p><p>And comes as Novo faces heated competition in the United States, the world's biggest drug market, against rival Eli Lilly.</p><p>The $150 billion weight-loss drug market is booming and Novo’s setting its sights on newer heights.  </p><p>:: Pfizer </p><p>The Danish pharma giant and another major rival Pfizer are in a bidding war over obesity biotech Metsera’s hottest experimental treatments. </p><p>The drugmakers are vying for access to its once-monthly GLP-1 injectable.</p><p>Current popular injectables, including Novo’s Wegovy and Eli Lilly’s Zepbound, are weekly shots. </p><p>Metsera is one of several companies developing experimental weight-loss drugs.</p><p>The move signals an aggressive turn by Novo Nordisk a week after the ousting of most of the company's board.</p><p>That was over concerns it was not moving fast enough in the obesity market.</p></body>

Description: We recently published 10 Stocks with Outstanding Gains; 9 on Record Highs. Metsera Inc. (NASDAQ:MTSR) is one of the best-performing stocks on Thursday. Metsera rallied to a fresh all-time high on Thursday, as investor optimism was bolstered by a billion-dollar bidding war between pharmaceutical giants Pfizer Inc. and Novo Nordisk. In intra-day trading, Metsera Inc. […]

Description: U.S. drugmaker may leverage political ties as takeover battle intensifies

Description: Record performance of its GLP-1 drugs sent shares in Eli Lilly soaring almost 4% after its earnings call on Thursday.

Description: Earnings preview of key companies reporting in the coming week and what to look out for.

Description: Pfizer Inc. (NYSE:PFE) is one of the stocks Jim Cramer recently talked about. During the lightning round, when a caller asked about the stock, Cramer commented: “I don’t know what to say about Pfizer. I mean, it’s got that yield of 7%. It bought that Seagen. I thought it was going to change it. But […]

Description: Lilly’s quarterly results Thursday, combined with Novo Nordisk’s unsolicited offer for a startup, confirm the $72 billion anti-obesity market is among pharma’s hottest.

Description: A surprise bid sparks a fiery corporate showdown in the obesity drug race

Description: ↘️ Chipotle Mexican Grill (CMG): The restaurant chain posted a drop in net income and quarterly revenue missed forecasts. Chipotle said economic strains were turning customers away from its stores. Shares slid 18% Thursday.

Description: Alnylam stock took a hit Thursday after the biotech company said it received a subpoena from the U.S. government related to its four drugs.

Description: Novo Nordisk kicked off a battle with Pfizer on Thursday, making an unsolicited $6.5 billion bid for obesity-focused Metsera.

Description: The bond sale comes a day after Chief Executive Officer Mark Zuckerberg warned that the company would spend even more aggressively on artificial intelligence in the coming year. Morgan Stanley expects big tech companies known as hyperscalers to spend about $3 trillion on infrastructure like data centers between now and the end of 2028, with roughly half of that likely financed through the corporations’ cash flows. Thursday’s bond sale is the biggest high-grade note offering since 2023, when Pfizer Inc. sold $31 billion of debt.

Description: <body><p>STORY: A bidding war is heating up in the race for the next blockbuster obesity drug.</p><p>Novo Nordisk on Thursday launched a surprise bid for U.S. biotech firm Metsera, hijacking an offer from Pfizer as the two jostle for advantage in the highly lucrative weight loss drug market.</p><p>The news sent shares of Metsera, which were already up nearly 100% since January, soaring more than 23% on Thursday.</p><p>Denmark's Novo Nordisk, maker of Wegovy and Ozempic, is offering up to $8.5 billion for Metsera.</p><p>That tops Pfizer’s bid of $7.3 billion.</p><p>Metsera says Novo’s offer is “superior” and has given Pfizer four days to respond.</p><p>Pfizer said Novo had made a previous bid for Metsera that was rejected.</p><p>It called Novo's revised offer "reckless" and bad for competition, adding it would "pursue all legal avenues" to defend its rights in the deal.</p><p>Novo declined to comment on its previous bid, which was confirmed by several other sources.</p><p>The company told Reuters its current offer - which values Metsera at $9 billion - underscored its commitment to investing in the US.</p><p>Both Novo and Pfizer want access to Metsera's experimental lineup.</p><p>They include a weight loss candidate drug that would only need to be injected once a month, unlike Novo's own Wegovy.</p><p>Novo's offer comes a week after the company ousted most of its board members over concerns it was not moving fast enough in the obesity market, where it competes with main rival Eli Lilly.</p><p>Meanwhile, shares of Lilly rose on Thursday after the company raised its full-year profit and revenue forecasts.</p><p>Lilly, which makes injectable weight loss drugs Zepbound and Mounjaro, said its experimental weight-loss *pill* will be submitted to the U.S. Food and Drug Administration this quarter for review.</p></body>

Description: Investing.com -- Pfizer is preparing to sue Metsera and potentially Novo Nordisk after the Danish drugmaker outbid Pfizer for the U.S. obesity biotech firm, according to a Semafor report Thursday.

Description: Denmark’s Novo offers $56.50 a share in cash for Metsera, plus potentially a further $21.25 a share based on clinical and regulatory milestones.

Description: CorMedix and Theravance take sharply different routes to small-cap biotech growth - one fueled by sales traction, the other by pipeline promise.

Description: Guardant Health (GH) shares soared 26% amid heavy trading after the company reported overnight impro

Description: Two of the world’s largest pharmaceutical companies are locked in a bidding war for the maker of a weight-loss drug that could help patients avoid succumbing to “Ozempic face”.

Description: Novo Nordisk, maker of weight-loss and diabetes jabs Ozempic and Wegovy, has a bold new boss in Maziar Mike Doustdar. His unusually aggressive...

Description: Yahoo Finance's John Hyland tracks today's top moving stocks and biggest market stories in this Market Minute, including Chipotle (CMG) shares dropping and dragging other fast-casual chains lower in response to the company's consumer pullback observations, Meta Platforms (META) reportedly raising $125 billion in bond sales, and Novo Nordisk (NVO) entering into a bidding war with Pfizer (PFE) for Metsera (MTSR). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Description: Pfizer says ready to ‘pursue all legal avenues to enforce its rights’ against competing bid from Ozempic and Wegovy maker

Description: The Nasdaq Composite and S&P 500 Index were both down in late-morning trading Thursday, while the Do

Description: While Pfizer called the bid “reckless”, Metsera disagrees, stating that it will review the “superior proposal”.

Description: UAE Interventional Cardiology Devices Market UAE Interventional Cardiology Devices Market Dublin, Oct. 30, 2025 (GLOBE NEWSWIRE) -- The "UAE Interventional Cardiology Devices Market, By Region, Competition, Forecast and Opportunities, 2020-2030F" report has been added to ResearchAndMarkets.com's offering.The UAE Interventional Cardiology Devices Market was valued at USD 58.25 Million in 2024, and is expected to reach USD 78.42 Million by 2030, rising at a CAGR of 5.08% The UAE interventional car

Description: Lilly said Thursday that its top-selling drugs, Mounjaro and Zepbound, brought in more than $10 billion combined during the recently completed third quarter. Separately, Danish drugmaker Novo Nordisk announced plans to buy Metsera Inc. in a deal that could be worth up to $9 billion.

Description: The drugmaker Eli Lilly reports its third-quarter results early Thursday, as questions loom about what kind of deal it will reach with the Trump administration over the price of its weight-loss drug. Lilly shares are up about 5% this year. Lilly appears to have triumphed over Novo Nordisk in the battle for the weight-loss market.

Description: Merck shares have floundered this year, as the company speeds like a whistling locomotive toward the expiration of the patents protecting its megablockbuster cancer immunotherapy Keytruda. Executives have a shot at reassuring the market on Thursday, when the company reports its third quarter results, but analysts aren’t optimistic. “We see a choppy 3Q print,” Cantor analyst Carter Gould wrote early this month.

Description: ​Pfizer Inc. (NYSE:PFE) is one of the Best Stocks to Buy for High Returns Heading into 2026. On October 27, Berenberg Bank analyst Luisa Hector maintained a Hold rating on Pfizer Inc. (NYSE:PFE) with a price target of $25. ​Earlier on October 22, Tim Andreson from Bank of America Securities reiterated a Hold rating with […]

Description: Pfizer has underperformed the broader market over the past year, but analysts are cautiously optimistic about the stock’s prospects.

Description: At Yahoo Finance Invest, an influential lineup of leaders across business, politics, and finance will convene to discuss what's next in markets, AI, cryptocurrency, and more.

Description: LLY's rapid dealmaking spree across biotech and gene therapy aims to expand its pipeline beyond cardiometabolic drugs and fuel long-term growth.

Description: The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant challenges, whether it’s stagnating growth, heavy debt, or disruptive new competitors.

Description: Pfizer (PFE) closed at $24.5 in the latest trading session, marking a -1.09% move from the prior day.

Description: Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Ted W. Love, M.D., has been appointed to the Company's Board of Directors, effective December 1, 2025. Dr. Love brings more than 30 years of expertise in drug development and global commercialization to the Company's Board.

Description: There’s no better way to generate passive income than dividend stocks. If a stock has a dividend yield higher than the common benchmark, such as the S&P 500, it could be a worthwhile investment. The dividend yield of the S&P 500 averages 1.2%, nearing its record low. Fortunately, there are several dividend stocks with a ... 5 High-Yield Stocks to Anchor Your Portfolio for Half a Decade

Description: The democratization of investing started with discount brokers slashing commissions and advanced through no-transaction-fee trading on apps like Robinhood (NASDAQ:HOOD) and Fidelity. Now, it no longer takes a lot of money to make money on Wall Street, as investors can buy fractional shares with as little as $5 or $10. That opens doors for everyday ... 3 Stocks Under $30: Where to Put $1,000 to Work Today

Description: MRK faces pressure from weak vaccine sales and rising competition, but strong oncology growth and new launches could support a rebound.

Description: Relay, Fate and Verastem advance promising cancer therapies, strengthening their pipelines in a rapidly evolving oncology market.

Description: CRMD's Q3 momentum, fueled by DefenCath's strong uptake and Melinta's revenue boost, positions the stock for continued growth.

Description: Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Description: In a gripping new release from Skyhorse Publishing, molecular biologist and whistleblower Becky McClain lays bare her harrowing journey in "Exposed," a book that promises to shake the foundations of corporate accountability and government oversight within the biotech industry. Set for wide release on October 28, "Exposed" chronicles McClain's years-long battle against pharmaceutical giant Pfizer, following her allegations of unsafe laboratory practices and the retaliation she says she endured fo

Description: Key Insights Institutions' substantial holdings in Pfizer implies that they have significant influence over the...

Description: The United States Adult Vaccine Market is projected to soar to US$ 11.10 billion by 2033, up from US$ 6.55 billion in 2024, with a steady CAGR of 6.03% between 2025 and 2033. This growth is propelled by increased awareness, advancements in biotechnology, and robust government support. The market is driven by the demand for vaccines tackling influenza, shingles, and hepatitis, with states like California, Texas, New York, and Florida leading adoption due to strong healthcare infrastructures. Desp

Description: Some of the largest drugmakers in the world are trading at attractive valuations. Are they worth buying?

Description: Saint-Herblain (France), October 27, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that its senior management will present and participate in 1-on-1 meetings with institutional investors at upcoming investor conferences in the United States and Europe. Valneva will host moderated “fireside chat” presentations to discuss the Company’s key value drivers and upcoming catalysts, primarily the upcoming Phase 3 trial outcomes for VLA15, the Company

Description: This pharma giant is entering the rapidly expanding market for weight loss drugs.

Description: The pharma giant is slated to report its latest quarterly numbers next week.

Description: Bristol-Myers Squibb's Q3 results hinge on rising demand for new therapies like Opdivo and Camzyos amid legacy-drug declines.

Description: These two healthcare giants are doing what they need to do to get their businesses rocking and rolling again.

Description: Vertex appears to be by far the better buy right now.

Description: If you are looking for high yields in the healthcare sector, here are three choices. Make sure you understand the risks before you buy them.

Description: Can the pharma giant offset potential losses from its megablockbuster with a strong suite of contenders?

Description: Five of the highest-yielding S&P 500 stocks offer incredible, dependable yields from quality blue-chip companies you can buy and hold forever.

Description: ​Pfizer Inc. (NYSE:PFE) is one of the Most Undervalued Long Term Stocks to Buy Right Now. On October 19, Pfizer Inc. (NYSE:PFE) and Astellas Pharma US Inc. announced final overall survival results from their Phase 3 EMBARK study. ​The study evaluated XTANDI in combination with leuprolide as a monotherapy for men with non-metastatic hormone-sensitive prostate […]

Description: Looking at high-yield healthcare stocks? These three stand out (but one has a slight skew to its story).

Description: Both companies are monsters in their industry and are poised to thrive.

Description: Sanofi stock jumped early Friday on better-than-expected third-quarter sales and earnings, and a strong showing from Dupixent.

Description: The Food and Drug Administration’s approval of the cancer drug Blenrep late Thursday offered some vindication for GSK, which has been battling for years to get the treatment back on the market, but the details weren’t quite good enough to satisfy investors. GSK American depositary receipts jumped in the final moments of trading on Thursday, when news of the approval crossed the wire. As investors examined the company update, however, sentiment reversed.

Description: Bristol Myers edges past Pfizer as the stronger oncology pick, backed by new drug launches, acquisitions and pipeline strength

Description: LLY's oncology portfolio, led by Verzenio, is set for double-digit growth as investors eye Q3 results beyond its obesity drugs.

Description: Recently, Zacks.com users have been paying close attention to Pfizer (PFE). This makes it worthwhile to examine what the stock has in store.

Description: Pfizer Singapore and BioNTech SE (Nasdaq: BNTX, "BioNTech") today announced that the Health Sciences Authority has approved the companies' LP.8.1-adapted monovalent COVID-19 vaccine (COMIRNATY® LP.8.1; COVID-19 Vaccine, mRNA) for use in individuals 6 months of age and older, according to official recommendations*. This marks Singapore as the first country in Southeast Asia to receive full approval for the latest COVID-19 vaccine.

Description: Shares rose after a jump in sales of the blockbuster Dupixent drug and robust pharmaceutical launches delivered higher revenue and adjusted earnings.

Description: If you’re eyeing Pfizer stock and wondering what’s next, you’re definitely not alone. The last few years have been a roller coaster for this healthcare heavyweight, and plenty of investors are watching closely. Should you hold, buy more, or consider moving on? Let’s start by looking at what’s been moving the needle recently. Pfizer’s shares are up 1.8% over the last week and have gained 2.2% over the past month. But zooming out gives a different angle, with the stock down 7.3% year-to-date...

Description: Investors use dividend-paying funds for portfolio diversification, viewing these companies as more trustworthy and better capital stewards.

Description: US pricing pressures come amid aggressive deal-making moves by Roche to bolster its internal pipeline.

Description: The strong earnings report from Medpace Holdings which runs clinical trials to test biotech companies’ new drugs, offers more evidence that the biotech sector is on the rebound. Medpace said late Wednesday that it had $789 million in new orders in the third quarter, up about 49% from the year-ago period. Its clinical trial backlog was up 2.5% from the 2024 third quarter, signaling an improving environment for the small- and midsize biotechs that make up most of its clients.

Description: Lilly stock climbs nearly 10% in a month amid a broader recovery in the drug and biotech sector.

Description: The United States Chronic Obstructive Pulmonary Disease (COPD) Market is projected to grow from US$ 3.97 billion in 2024 to US$ 4.92 billion by 2033, at a CAGR of 2.42%. Factors driving this growth include an aging population, heightened smoking rates, and environmental influences. The demand for innovative inhalers, biologics, and rehabilitation programs is rising. Key segments include chronic bronchitis and emphysema, with treatment options spanning drugs, oxygen therapy, and surgery. States l

Description: The pharma group lifted its guidance citing strong results to date, and reported a rise in sales excluding currency movements.

Description: New Spherix Global Insights data reveal growing physician demand for therapies that reduce treatment burden and elevate patient experience.EXTON, PA, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Hematologists across the United States are redefining what “success” looks like in hemophilia treatment, according to the latest findings from Market Dynamix™: Hemophilia (US) 2025 and the accompanying Launch Dynamix™ trackers for Qfitlia (Sanofi), Hympavzi (Pfizer), and Alhemo (Novo Nordisk). The new research from

Description: AbbVie's 30% surge in six months is powered by booming sales of Skyrizi and Rinvoq and renewed strength across oncology and neuroscience.

Description: Flagship Pioneering, a scientific innovation engine for transformative platforms and products, today unveiled Expedition Medicines™, a company pioneering generative covalent chemistry to expand the boundaries of medicine. Following three years of in-house development, Flagship has committed an initial $50 million to support scaling Expedition's platform for generating small molecule medicines to any target and to further develop its discovery programs in oncology, immunology, and other well-defi

Description: The scientific services company recorded third-quarter sales of $11.12 billion on the back of growth in its life sciences business.

Description: The life sciences and diagnostics company posted sales of $6.05 billion and stands to benefit from an increase in pharmaceutical-research investment as tariff uncertainty eases.

Description: Bristol Myers leans on new drugs like Opdivo and Reblozyl to offset pressure from generics as its Growth Portfolio drives stability.

Description: Dividend stocks with high yields can be great investment opportunities, but those yields can also be red flags.

Description: ​Pfizer Inc. (NYSE:PFE) is one of the Best Growth Stocks Under $25 to Buy Right Now. On October 14, Pfizer Inc. (NYSE:PFE) announced positive results from its Phase 3 HER2CLIMB-05 trial. ​The trial tested the kinase inhibitor TUKYSA with first-line combination therapy for patients with human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. […]

Description: Pfizer (PFE) shares have been inching upward recently, sparking some fresh attention from investors looking to understand what is driving the action. Over the past month, the stock has gained about 3% despite mixed signals across the sector. See our latest analysis for Pfizer. Pfizer’s recent climb comes even as the broader sector faces some headwinds. While there’s been a modest 2.75% share price return over the past month, the longer-term picture is less rosy, with a 1-year total...

Description: Amazon has grown since it launched as an online bookstore in 1995 to become the dominant player in web hosting 30 years later. Amazon Web Services (AWS) was launched in 2006, and over the last decade, it has become the largest cloud computing provider in the world. AWS generated $107.6 billion in ...

Description: Pfizer's Q3 results are set to reveal mixed trends across non-oncology drugs, with strong Eliquis and Paxlovid sales offset by weakness in Abrysvo and Xeljanz.

Description: ABBV's oncology lineup, spanning blood and solid tumor drugs, faces modest Q3 growth as new launches offset Imbruvica's decline.

Description: CorMedix's DefenCath, the first FDA-approved antimicrobial catheter lock, is expected to drive Q3 growth as new Melinta drugs add to momentum.

Description: Pfizer (PFE) and Astellas Pharma US said Sunday that the drug combination Xtandi and leuprolide for

Description: They are both yielding above 5%.

Description: NEW YORK & NORTHBROOK, Ill., October 19, 2025--Pfizer Inc. (NYSE: PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") today announced final overall survival (OS) results from the Phase 3 EMBARK study evaluating XTANDI® (enzalutamide), in combination with leuprolide and as monotherapy, in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC; also known as nonmetastatic castration-sensitive prostate cancer or nmCSPC) with biochemical recurrence (BCR) a

Description: NEW YORK, October 19, 2025--Pfizer Inc. (NYSE: PFE) today announced updated follow-up results from the single-arm Phase 2 PHAROS trial evaluating BRAFTOVI® (encorafenib) + MEKTOVI® (binimetinib) for the treatment of adults with metastatic non-small cell lung cancer (mNSCLC) with a BRAF V600E mutation. In treatment-naïve patients, the median overall survival (OS) was 47.6 months (95% confidence interval [CI], 31.3, not estimable) after a median follow-up of 52.3 months. In previously treated pati

Description: Astellas Pharma and Pfizer recently announced positive Phase 3 results for PADCEV plus KEYTRUDA in muscle-invasive bladder cancer, while Pfizer reported encouraging findings for TUKYSA in the first-line treatment of HER2-positive metastatic breast cancer. These late-stage clinical successes highlight Pfizer's strengthened oncology pipeline and its potential to address significant treatment gaps, particularly for patients ineligible for standard therapies. We'll now explore how the promising...

Description: Pharma titans Merck, Pfizer and Astellas Pharma are delivering an "enormous new hope" for patients with an aggressive form of bladder cancer.

Description: Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") and Pfizer Inc. (NYSE: PFE) today announced positive results from the pivotal Phase 3 EV-303 clinical trial (also known as KEYNOTE-905) for PADCEV™ (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with KEYTRUDA™ (pembrolizumab), a PD-1 inhibitor. The study evaluated the combination in patients with muscle-invasive bladder cancer (MIBC) who are ineligible for or declined cisplatin-based

Description: Analysts spotlight Home Depot, Boeing, and Progressive in today's top Zacks reports, revealing growth drivers, risks, and key performance trends.

Description: Pfizer (PFE) concluded the recent trading session at $24.51, signifying a +1.16% move from its prior day's close.

Description: Barron’s called Holz to ask about what’s happened to the biotech sector since our healthcare roundtable.

Description: JNJ's strong Q3 results, upbeat sales outlook and expanding drug pipeline highlight resilience despite Stelara LOE.

Description: DURHAM, N.C., October 17, 2025--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced 96-week findings from PASO DOBLE (GeSIDA 11720 study) showing that Dovato (dolutegravir/lamivudine [DTG/3TC]) is as effective as Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide fumarate [BIC/FTC/TAF]) in maintaining virological suppression in adults with HIV-1. Individuals taking Dovato also experienced statistically signifi